Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy
Study Details
Study Description
Brief Summary
The objective of this trial is to determine whether an opioid-free general anesthetic (OFA) technique utilizing ketamine, dexmedetomidine, lidocaine, and gabapentin can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques. It is expected that this OFA regimen will have a measurable reduction on postoperative respiratory depression in children with sleep-disordered breathing.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
|
Phase 3 |
Detailed Description
The objective of this trial is to determine whether an opioid-free general anesthetic can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Opioid-free anesthesia Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis |
Drug: Acetaminophen, gabapentin
acetaminophen 15 mg/kg, gabapentin 10 mg/kg
Other Names:
Drug: Ketamine , Lidocaine , Dexmedetomidine
Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
Other Names:
Drug: Dexamethasone , Ondansetron
Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
Other Names:
Drug: Sevoflurane
Sevoflurane (dose titrated to effect)
Other Names:
|
Active Comparator: Opioid-sparing anesthesia Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis |
Drug: Acetaminophen
acetaminophen 15 mg/kg
Other Names:
Drug: Fentanyl, Dexmedetomidine
Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
Other Names:
Drug: Dexamethasone , Ondansetron
Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
Other Names:
Drug: Sevoflurane, Fentanyl
Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Respiratory depression [24 hours following surgery]
Number of desaturation events (oxygen saturation by pulse oximetry (SPO2) <90%) as measured by a Masimo Radical-7 pulse oximeter during the first postoperative night's sleep
Secondary Outcome Measures
- Quantified opioid consumption [24 hours following surgery]
Quantified opioid consumption
- Pediatric Agitation Emergence Delirium (PAED) scale [24 hours following surgery]
Pediatric Agitation Emergence Delirium (PAED) scale
- Face Legs Activity Cry Consolability (FLACC) scale [24 hours following surgery]
Face Legs Activity Cry Consolability (FLACC) scale
- Time until Post Anesthesia Care Unit (PACU) discharge readiness [24 hours following surgery]
Time until Post Anesthesia Care Unit (PACU) discharge readiness
- Other adverse effects [24 hours following surgery]
Other adverse effects
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients aged 0-12 years with Sleep Disordered Breathing (SDB) who are scheduled for elective Tonsillectomy/AdenoTonsillectomy (T/AT) will be recruited at Royal University Hospital, Saskatoon, Saskatchewan.
Exclusion Criteria:
- age > 12; American Society of Anesthesiologists (ASA) Classification > IV; significant cardiorespiratory, neurological, craniofacial, hepatic, renal, or genetic disorders, excluding SDB; concomitant surgical procedures other than myringotomy and tubes; and allergy to any of the study drugs
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Royal University Hospital | Saskatoon | Saskatchewan | Canada | S7N 0W8 |
Sponsors and Collaborators
- University of Saskatchewan
Investigators
- Principal Investigator: Jon Gamble, MD, University of Saskatchewan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BIO 16-255